BIVIW
BIOVIE INC.Warrants of BIOVIE INC. · BIVI stock page →
—
Market cap
$2.2M
Nano cap
1 year
−34.4%
from $1.89 · Oct 27
30 days
−19.5%
from $1.54
52-week range
$0.9640–2.28
−46% from high · low Aug 18
Avg volume 20D
193.9K
shares / day
Short interest
🔒 Subscribers only
New fund stakes
0
Q4 2025 13F · 0 exits
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- X Jul 15 Short interest falls 97.5% to 185
- E Sep 15 Trading halt: Trading Halt: BIVIW — T1 (News Pending)
- X Sep 15 Short interest falls 90.7% to 43.3K
- E Sep 15 Trading halt: Halt Resumed: BIVIW — trading resumed after T3 (News and R…
- E Sep 15 Trading halt: Trading Halt: BIVIW — T2 (News Released)
- E Sep 15 Trading halt: Trading Halt: BIVIW — T3 (News and Resumption Times)
- X Sep 30 Short interest falls 51.6% to 20.9K
- E Oct 23 Trial readout: Results Pending: NE3107 (Phase 2) — Completed 78d ago
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q4 2025: 0 added (0 new), 1 trimmed or exited.
- TrendDOWNTREND
24% below its 50-day average.
Who's buying
13F· Q4 20250
new positions
0
exits
| Fund | Move | Value |
|---|---|---|
| UBS Group AG | TRIM | $115.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 Clinical trial readout
Results Pending: NE3107 (Phase 2) — Completed 78d ago
Trial: NE3107 in Adults With Neurological Symptoms of Long COVID Sponsor: BioVie Inc. Phase: Phase 2
Dec 31, 2025 Inst.
UBS Group AG — TRIM
425 shares ($115.00)
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Short side
FINRA· Oct 15, 2026🔒 Subscribers only
shares short
Trading halts
| Sep 15, 2026 | Resumption Scheduled | Resumed |
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 22, 2026
Trial readout
Results Pending: NE3107 (Phase 2) — Completed 78d ago
Trial: NE3107 in Adults With Neurological Symptoms of Long COVID Sponsor: BioVie Inc. Phase: Phase 2 | Completed: 2026-08-06 Conditions: Long COVID…
Sep 15, 2026
Trading halt
Halt Resumed: BIVIW — trading resumed after T3 (News and Resumption Times)
Halted 2026-09-15T11:25:00.000Z | Resumed 2026-09-15T12:05:00.000Z
Sep 15, 2026
Trading halt
Trading Halt: BIVIW — T1 (News Pending)
BioVie Inc Wt | Market: NASDAQ | Code: T1 — News Pending
Sep 15, 2026
Trading halt
Trading Halt: BIVIW — T2 (News Released)
BioVie Inc Wt | Market: NASDAQ | Code: T2 — News Released
Sep 15, 2026
Trading halt
Trading Halt: BIVIW — T3 (News and Resumption Times)
BioVie Inc Wt | Market: NASDAQ | Code: T3 — News and Resumption Times